Merit buys hemostatic device maker Biolife for $120M

Merit buys hemostatic device maker Biolife for $120M

Merit CEO Fred Lampropoulos said Biolife’s StatSeal and WoundSeal devices “address an estimated $350 million global market opportunity.”

Manatee medical manufacturer acquired for $120 million

Biolife has become a subsidiary of Merit Medical Systems.

Merit Medical acquires haemostatic device manufacturer Biolife - Interventional News

Merit Medical Systems has announced that it has acquired Biolife Delaware in a merger transaction through which Biolife has become a wholly-owned subsidiary of Merit. Biolife manufactures patented haemostatic devices under the brand names StatSeal and WoundSeal. A press release made by Merit states that the aggregate transaction consideration, paid in cash and assumption of Biolife liabilities, was approximately US$120 million. This strategic ac…

Merit Medical acquires haemostatic device manufacturer Biolife for $120m

Merit Medical Systems has acquired US-based Biolife Delaware, a manufacturer of haemostatic devices, in a $120m deal.The post Merit Medical acquires haemostatic device manufacturer Biolife for $120m appeared first on Medical Device Network.